Tonix Pharmaceuticals’ (TNXP) Buy Rating Reaffirmed at Aegis
Tonix Pharmaceuticals (NASDAQ:TNXP)‘s stock had its “buy” rating restated by stock analysts at Aegis in a report released on Friday.
TNXP has been the subject of several other reports. ValuEngine upgraded shares of Tonix Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Friday, September 1st. Dawson James reiterated a “buy” rating and set a $9.00 price objective on shares of Tonix Pharmaceuticals in a research report on Wednesday, August 23rd. Roth Capital upgraded shares of Tonix Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $6.00 price objective for the company in a research report on Friday, August 18th. They noted that the move was a valuation call. Finally, Drexel Hamilton started coverage on shares of Tonix Pharmaceuticals in a research report on Tuesday, August 22nd. They set a “buy” rating for the company. One analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $8.33.
Shares of Tonix Pharmaceuticals (NASDAQ:TNXP) traded down $0.06 during trading hours on Friday, hitting $3.78. 48,097 shares of the stock traded hands, compared to its average volume of 344,198. Tonix Pharmaceuticals has a one year low of $2.85 and a one year high of $9.40.
TRADEMARK VIOLATION WARNING: This piece of content was reported by American Banking News and is the property of of American Banking News. If you are reading this piece of content on another publication, it was stolen and republished in violation of U.S. and international trademark and copyright laws. The correct version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/12/07/tonix-pharmaceuticals-tnxp-buy-rating-reaffirmed-at-aegis.html.
About Tonix Pharmaceuticals
Tonix Pharmaceuticals Holding Corp., a clinical-stage pharmaceutical company, engages in developing pharmaceutical products for central nervous system disorders. The companys lead program focuses on post-traumatic stress disorder (PTSD) that is characterized by chronic disability, inadequate treatment options, high utilization of healthcare services, and economic burden.
Receive News & Ratings for Tonix Pharmaceuticals Holding Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tonix Pharmaceuticals Holding Corp. and related companies with MarketBeat.com's FREE daily email newsletter.